Pfizer(US:PFE) 智通财经网·2025-12-16 13:29Core Viewpoint - Pfizer (PFE.US) is facing stagnant sales growth as it attempts to revamp its drug portfolio through costly acquisitions, with projected revenues for 2026 expected to be between $59.5 billion and $62.5 billion, aligning with Wall Street expectations [1] Group 1: Financial Projections - Pfizer anticipates minimal to no sales growth for the upcoming year, with expected sales of $62 billion for the current year, consistent with previous guidance [1] - The company forecasts adjusted earnings per share for next year to be between $2.80 and $3.00 [1] - Revenue from COVID-related products is projected to decline by approximately $1.5 billion to $5 billion next year [1] Group 2: Cost-Cutting Measures - Pfizer plans to implement significant cost-cutting measures, aiming to save over $7 billion by 2027, with most savings expected to be realized in the coming year [1] - The company intends to reinvest $500 million of the savings into research and development [2] Group 3: Acquisitions and Competition - Pfizer has recently acquired Metsera for $10 billion to enhance its drug pipeline in the obesity treatment sector, although the drugs are still in early development stages [2] - The company is also facing increased competition for key products like the pneumonia vaccine Prevnar and the heart disease treatment Vyndaqel [2] - Previous acquisitions, including a $43 billion deal for cancer drug maker Seagen, have not yet yielded sufficient success, with analysts predicting flat or declining sales at least until 2031 [3]